findmyKOL

Arvind Nishtala, MD

Basic profile

Marin Endocrine Care and Research

ORCIDNone on fileNPI
RegionLarkspur, CA · WestSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Arvind Nishtala is a Cardiology physician affiliated with Marin Endocrine Care and Research. OpenAlex indexes 24 publications with 257 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
24publications

Distinct works indexed by OpenAlex.

257citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    81.5%
    Statin22.9%
    Atorvastatin Calcium52%Rosuvastatin Calcium38%Pravastatin Sodium6%Simvastatin4%
    Part D<11 patients
    Beta blocker17.8%
    Metoprolol Succinate58%Metoprolol Tartrate19%Carvedilol14%Atenolol6%Propranolol Hcl3%
    Part D<11 patients

    + 14 more classes in this area

  • Blood & clotting

    14.9%
    Factor Xa inhibitor11.5%
    Eliquis79%Xarelto21%
    Part D68 patients
    P2Y12 inhibitor2.7%
    Clopidogrel81%Brilinta19%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    3.2%
    Potassium supplement1.6%
    Potassium Chloride100%
    Part D21 patients
    SGLT2 inhibitor1.5%
    Jardiance100%
    Part D17 patients
Where care is delivered (Part B)28.6% facility · 71.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”